Skip NavigationSkip to Content

NCI at Frederick Scientific Publications Advanced Search

Search
  1. NCI-F Publications

Search
  1. Year Published:

Your search returned 10 results.
User Information
Export Records
  1. 1.   Linked dual-class HIV resistance mutations are associated with treatment failure
  2. Boltz,Valerie; Shao,Wei; Bale,Michael; Halvas, Elias; Luke,Brian; McIntyre, James A.; Schooley, Robert T.; Lockman, Shahin; Currier, Judith S.; Sawe, Fred; Hogg, Evelyn; Hughes, Michael D.; Kearney,Mary; Coffin, John M.; Mellors, John W.
  3. JCI INSIGHT. 2019, OCT 3; 4(19):
  1. 2.   Lack of Effect from a Previous Single Dose of Nevirapine on Virologic and Immunologic Responses After 6 Months of Antiretroviral Regimens Containing Either Efavirenz or Lopinavir-Ritonavir
  2. Dlamini, J. N.; Hu, Z. H.; Somaroo, H.; Highbarger, H. C.; Follmann, D. A.; Dewar, R. L.; Pau, A. K.
  3. Pharmacotherapy. 2011, Feb; 31(2): 158-163.
  1. 3.   Associations of 9p21 variants with cutaneous malignant melanoma, nevi, and pigmentation phenotypes in melanoma-prone families with and without CDKN2A mutations
  2. Yang, X. R.; Liang, X. Y.; Pfeiffer, R. M.; Wheeler, W.; Maeder, D.; Burdette, L.; Yeager, M.; Chanock, S.; Tucker, M. A.; Goldstein, A. M.
  3. Familial Cancer. 2010, Dec; 9(4): 625-633.
  1. 4.   A Novel Molecular Mechanism of Dual Resistance to Nucleoside and Nonnucleoside Reverse Transcriptase Inhibitors
  2. Nikolenko, G. N.; Delviks-Frankenberry, K. A.; Pathak, V. K.
  3. Journal of Virology. 2010, May; 84(10): 5238-5249.
  1. 5.   Low Frequency Nonnucleoside Reverse-Transcriptase Inhibitor-Resistant Variants Contribute to Failure of Efavirenz-Containing Regimens in Treatment-Experienced Patients
  2. Halvas, E. K.; Wiegand, A.; Boltz, V. F.; Kearney, M.; Nissley, D.; Wantman, M.; Hammer, S. M.; Palmer, S.; Vaida, F.; Coffin, J. M.; Mellors, J. W.
  3. Journal of Infectious Diseases. 2010, Mar; 201(5): 672-680.
  1. 6.   Optimization of allele-specific PCR using patient-specific HIV consensus sequences for primer design
  2. Boltz, V. F.; Maldarelli, F.; Martinson, N.; Morris, L.; McIntyre, J. A.; Gray, G.; Hopley, M. J.; Kimura, T.; Mayers, D. L.; Robinson, P.; Mellors, J. W.; Coffin, J. M.; Palmer, S. E.
  3. Journal of Virological Methods. 2010, Mar; 164(1-2): 122-126.
  1. 7.   ARF functions as a melanoma tumor suppressor by inducing p53-independent senescence
  2. Ha, L.; Ichikawa, T.; Anver, M.; Dickins, R.; Lowe, S.; Sharpless, N. E.; Krimpenfort, P.; DePinho, R. A.; Bennett, D. C.; Sviderskaya, E. V.; Merlino, G.
  3. Proceedings of the National Academy of Sciences of the United States of America. 2007, Jun; 104(26): 10968-10973.
  1. 8.   Cytochrome P4502B6 (CYP2B6) G516T influences nevirapine plasma concentrations in HIV-infected patients in Uganda
  2. Penzak, S. R.; Kabuye, G.; Mugyenyi, P.; Mbamanya, F.; Natarajan, V.; Alfaro, R. M.; Kityo, C.; Formentini, E.; Masur, H.
  3. HIV Medicine. 2007, Mar; 8(2): 86-91.
  1. 9.   Selection and persistence of non-nucleoside reverse transcriptase inhibitor-resistant HIV-1 in patients starting and stopping non-nucleoside therapy
  2. Palmer, S.; Boltz, V.; Maldarelli, F.; Kearney, M.; Halvas, E. K.; Rock, D.; Falloon, J.; Davey, R. T.; Dewar, R. L.; Metcalf, J. A.; Mellors, J. W.; Coffin, J. M.
  3. Aids. 2006, Mar; 20(5): 701-710.
  1. 10.   Rarity of CDK4 germline mutations in familial melanoma
  2. Goldstein, A. M.; Chidambaram, A.; Halpern, A.; Holly, E. A.; Guerry, D.; Sagebiel, R.; Elder, D. E.; Tucker, M. A.
  3. Melanoma Research. 2002 12(1): 51-55.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel